CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...4849505152535455565758...39323933»
  • ||||||||||  Opdivo (nivolumab) / BMS, Tecentriq (atezolizumab) / Roche, Yervoy (ipilimumab) / BMS
    Unveiling a Novel CALCR::BRAF Fusion in a Case of Widely Metastatic Poorly Differentiated Neuroendocrine Lung Carcinoma (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_449;    
    Identification of this novel BRAF::CALCR fusion highlights the power of NGS and suggests therapeutic opportunities, since aberrant activation MAPK/ERK pathways may contribute to uncontrolled cell proliferation. The role of calcitonin and/or calcitonin gene-related peptide signaling is being explored.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Genetic Alterations in Carcinomas of the Urinary Bladder (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_377;    
    The alterations in DNA repair pathway account for 21.4%, RB1/TP53/cell cycle pathway 92.9% and RTK/Pi3K/RAS 78.6%. The most common gene mutations identified were TERT, TP53 and RB1.
  • ||||||||||  Inlyta (axitinib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
    Spectrum of Histologic Findings in Renal Cell Carcinoma Treated with Neoadjuvant Immune Checkpoint Inhibitor Therapy (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_363;    
    As neoadjuvant treatment is increasingly utilized for RCC, awareness of histologic features associated with ICI is critical for the pathologist. Best practices for the gross and microscopic examination have not been determined but should take into account the extensive treatment changes occurring in this setting.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Expression of Programmed Death Ligand-1 (PD-L1) in Cervical and Vulvar Carcinomas (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_337;    
    Our results suggest that most patients with cervical/vaginal and vulvar carcinomas express PD-L1. However, elucidating the prognostic and predictive significance of the PD-L1 expression levels requires larger studies.Clinical-Pathologic Data Based on Pembrolizumab Therapy
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Immunomodulatory Agent (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_212;    
    We describe a case with residual pigmentation, histiocytic response in the lamina propria, and erosion compatible with treatment response. It is important to recognize this pattern as treated metastatic melanoma and not viable residual tumor to prevent misdiagnosis; ancillary immunohistochemical and histochemical stains can assist to resolve this diagnostic dilemma.
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Uncharted Waters: Fatal PD-L1 Inhibitor (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_180;    
    A 58-year-old woman with type 2 diabetes and metastatic breast cancer without significant hepatitis history underwent bilateral mastectomy followed by immunotherapy with PD-L1 inhibitor atezolizumab...The treatment was discontinued; however, the patient deteriorated and expired 3 weeks after the biopsy. Extreme vigilance is essential for patients at risk of viral hepatitis or autoimmunity when using immunotherapy, as their combination may lead to a much worse outcome.
  • ||||||||||  sunitinib / Generic mfg.
    Seeding the Symphony (Exhibit Hall, Cristal Ballroom) -  Aug 28, 2024 - Abstract #CAP2024CAP_165;    
    The patient was given tablet sunitinib, and germline mutational studies were advised because of increased propensity of developing multicentric paragangliomas and pheochromocytomas/gastrointestinal stromal tumor. This case creates an awareness for physicians regarding how paragangliomas metastasize to liver by providing an insight into the diagnostic workup with neuroendocrine markers and molecular immunohistochemical stain to obtain a definitive diagnosis.
  • ||||||||||  Rituxan (rituximab) / Roche
    Review, Journal:  Recent advances in CD5+ diffuse large B-cell lymphoma. (Pubmed Central) -  Aug 28, 2024   
    Despite supporting evidence from retrospective studies, it is currently unclear whether dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) can improve outcomes in this population. Several new drugs, such as Bruton tyrosine kinase inhibitors (BTKi), BCL-2 inhibitors, and CXCR4 antagonists, as well as immunotherapy, may help to improve the prognosis of CD5+ DLBCL patients, but additional clinical explorations are needed to determine the optimal therapeutic strategy for this disease.
  • ||||||||||  Review, Journal:  Update on treatment of ANCA-associated vasculitis (Pubmed Central) -  Aug 28, 2024   
    Instead, renal allograft is not recommended, due to high incidence of relapse. Rituximab (RTX) is used for remission induction and maintenance in organ-threatening and non-organ-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)...The dosing of GC for remission induction in GPA and MPA is now lower than was previously used and additionally, avacopan is approved as a
  • ||||||||||  Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin
    Journal:  Atypical Presentation of Invasive Aspergillosis during Treatment with Mogamulizumab. (Pubmed Central) -  Aug 28, 2024   
    Paradoxically, worsening of the chronic pulmonary aspergillosis has been reported after nivolumab treatment, and immune reconstitution syndromes are usually seen during neutrophil recovery after intensive chemotherapy...We think that the immune restoration associated with Mogamulizumab (also supported by the concurrent clinical response of the skin lesions) could have been detrimental in this case, exacerbating a catastrophic immune response or alternatively masquerading the clinical progression of aspergillosis. Clinicians should be aware of immune reconstitution syndromes possibly leading to fatal outcomes in immunocompromised patients starting CCR-4 antagonists.
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS
    Journal:  Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center. (Pubmed Central) -  Aug 28, 2024   
    Safe and successful administration of cellular therapies handled and compounded by pharmacy department staff along with program validation requires a preemptive review utilizing a multidisciplinary approach for process development. This manuscript will provide a foundation based on consistency and transparency in effective cellular therapy sterile compounding and aseptic manipulation, proper handling and disposal procedures, increased communication through creation and optimization of treatment plans and order-sets, standardized medical center staff education, and development of policies and standard operating procedures for the entire health care team.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
    Journal:  Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results. (Pubmed Central) -  Aug 28, 2024   
    Randomized trials provide an evidence base for the SSc-ILD treatment recommendations put forth in the ACR/CHEST Guidelines for the treatment of ILD in people with systemic autoimmune rheumatic diseases. These guidelines will help inform clinical practice and highlight areas in which further research is needed.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Tagrisso (osimertinib) / AstraZeneca, Opdivo (nivolumab) / BMS
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Stage I and II nonsmall cell lung cancer treatment options. (Pubmed Central) -  Aug 28, 2024   
    Osimertinib may be used for resected stage IB to IIIA cancers which have relevant mutations (epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution). There are no fixed guidelines for follow-up, but most centres recommend 6-monthly CT scanning for the first 2-3?years after definitive treatment, followed by annual scans.
  • ||||||||||  MK-4830 / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient. (Pubmed Central) -  Aug 28, 2024   
    The patient was successfully treated with oral prednisone, which controlled the skin symptoms without interrupting ICI therapy. We emphasize that early diagnosis and treatment of low-grade lichenoid eruption can prevent the cessation of ICIs, thereby combining the benefits of managing irAEs and avoiding cancer progression, leading to a better long-term prognosis.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Journal, PD(L)-1 Biomarker:  Malignant Melanoma With Neural Marker-Positive Distant Organ Cancers. (Pubmed Central) -  Aug 28, 2024   
    Despite postoperative nivolumab treatment, metastases in the brain and lungs were observed...This case suggests two possibilities: the coexistence of malignant melanoma with neuroendocrine tumors or a transformation of melanoma into a neuroendocrine phenotype. This case highlights the need for clinicians to consider the potential for melanoma to lose typical markers and transform into neuroendocrine cancer.
  • ||||||||||  felzartamab (MOR202) / Biogen
    Journal:  Chronic Rejection After Kidney Transplantation. (Pubmed Central) -  Aug 28, 2024   
    In an exploratory phase 2 trial in late AMR, this compound has demonstrated potential in resolving molecular and morphologic rejection activity and injury, predominantly by targeting NK cell effector function. These findings inspire hope for effective treatments and emphasize the necessity of further pivotal trials focusing on chronic transplant rejection.
  • ||||||||||  Hepavac (IMA970A) / Immatics, CureVac, Imfinzi (durvalumab) / AstraZeneca
    Trial primary completion date, Combination therapy, IO biomarker:  A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) (clinicaltrials.gov) -  Aug 28, 2024   
    P1,  N=10, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jun 2024 --> Jun 2025
  • ||||||||||  Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
    Enrollment change:  ZBR: Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (clinicaltrials.gov) -  Aug 28, 2024   
    P2,  N=42, Recruiting, 
    Trial completion date: Dec 2026 --> Jul 2026 | Trial primary completion date: Dec 2026 --> Jul 2026 N=30 --> 42
  • ||||||||||  Enrollment closed, Enrollment change, Checkpoint inhibition, IO biomarker, Checkpoint block:  Exercise to Boost Response to Checkpoint Blockade Immunotherapy (clinicaltrials.gov) -  Aug 28, 2024   
    P1,  N=22, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting | N=32 --> 22